Contribution of cost to treatment nonadherence in the US breast cancer survivors: a population-based analysis.
Caiwei ZhengAnees B ChagparPublished in: Breast cancer research and treatment (2022)
Roughly 12% of breast cancer survivors who are prescribed medications within the first 5 years of their diagnosis will forego treatment due to cost. Family income and insurance status are key modifiable drivers of this.